An Israeli biotech is looking to make its name in the jam-packed CD47 space. Is bifunctionality the answer?
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement
Michael Ehlers is betting $40M that an AI outfit has figured out how to beat the blockbuster IL-2 challenge